OrienX 010

Drug Profile

OrienX 010

Alternative Names: OrienX010; Recombinant hGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; Recombinant hGM-CSF HSV - OrienGene Biotechnology; rhGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; rhGM-CSF HSV - OrienGene Biotechnology

Latest Information Update: 15 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OrienGene Biotechnology
  • Developer Beijing Bozhiyin T&S; OrienGene Biotechnology; START Shanghai
  • Class Cancer vaccines; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Cell membrane modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Mar 2016 Phase-I development is ongoing in China
  • 01 May 2012 Phase-I clinical trials in Solid tumours in China (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top